スタッカートアルプラゾラムの有効性と安全性をテストするための研究参加者の12歳以上の典型的な長時間の発作を伴う研究
スタッカートアルプラゾラムの有効性と安全性を評価するための二重盲検、無作為化、プラセボ対照、多施設、外来患者、並行群間研究
The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:UCB Cares
- 電話番号:0018445992273
- メール:UCBCares@ucb.com
研究連絡先のバックアップ
- 名前:UCB Cares
- 電話番号:1-844-599-2273 (USA)
- メール:UCBCares@ucb.com
研究場所
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85004
- 募集
- Ep0162 50506
-
Scottsdale、Arizona、アメリカ、85253
- 募集
- Ep0162 50720
-
-
Arkansas
-
Little Rock、Arkansas、アメリカ、72205
- 完了
- Ep0162 50494
-
-
California
-
Downey、California、アメリカ、90242
- 募集
- Ep0162 50118
-
La Jolla、California、アメリカ、92037
- 募集
- Ep0162 50416
-
Long Beach、California、アメリカ、90806
- 募集
- Ep0162 50702
-
Los Angeles、California、アメリカ、90095
- 引きこもった
- Ep0162 50505
-
Orange、California、アメリカ、92868
- 完了
- Ep0162 50492
-
Poway、California、アメリカ、92064
- 引きこもった
- Ep0162 50722
-
Sacramento、California、アメリカ、95817
- 募集
- Ep0162 50716
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06519
- 完了
- Ep0162 50367
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20037
- 募集
- Ep0162 50088
-
-
Florida
-
Boca Raton、Florida、アメリカ、33486
- 引きこもった
- Ep0162 50721
-
Gulf Breeze、Florida、アメリカ、32561
- 完了
- Ep0162 50515
-
Jacksonville、Florida、アメリカ、32224-1865
- 募集
- Ep0162 50342
-
Jacksonville、Florida、アメリカ、32209-6533
- 募集
- Ep0162 50508
-
Miami、Florida、アメリカ、33136
- 募集
- Ep0162 50199
-
Miami、Florida、アメリカ、33176
- 募集
- Ep0162 50676
-
Orlando、Florida、アメリカ、32806
- 完了
- Ep0162 50509
-
Rockledge、Florida、アメリカ、32955
- 募集
- Ep0162 50703
-
Tampa、Florida、アメリカ、33606
- 募集
- Ep0162 50308
-
-
Hawaii
-
Honolulu、Hawaii、アメリカ、96817
- 募集
- Ep0162 50323
-
-
Idaho
-
Boise、Idaho、アメリカ、83702
- 募集
- Ep0162 50512
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- 募集
- Ep0162 50493
-
Springfield、Illinois、アメリカ、62702
- 引きこもった
- Ep0162 50375
-
-
Indiana
-
Fort Wayne、Indiana、アメリカ、46804
- 募集
- Ep0162 50504
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40536
- 引きこもった
- Ep0162 50561
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70122
- 募集
- Ep0162 50517
-
New Orleans、Louisiana、アメリカ、70121
- 引きこもった
- Ep0162 50395
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- 引きこもった
- Ep0162 50093
-
Bethesda、Maryland、アメリカ、20817
- 引きこもった
- Ep0162 50488
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02118
- 募集
- Ep0162 50615
-
Boston、Massachusetts、アメリカ、02215
- 完了
- Ep0162 50047
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- 完了
- Ep0162 50110
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- 募集
- Ep0162 50507
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89128
- 引きこもった
- Ep0162 50499
-
-
New Jersey
-
Neptune City、New Jersey、アメリカ、07753
- 引きこもった
- Ep0162 50626
-
New Brunswick、New Jersey、アメリカ、08901
- 募集
- Ep0162 50299
-
-
New York
-
Buffalo、New York、アメリカ、14221
- 募集
- Ep0162 50497
-
New Hyde Park、New York、アメリカ、11042
- 完了
- Ep0162 50625
-
New York、New York、アメリカ、10016
- 募集
- Ep0162 50298
-
New York、New York、アメリカ、10029
- 募集
- Ep0162 50490
-
New York、New York、アメリカ、10075
- 募集
- Ep0162 50518
-
Rochester、New York、アメリカ、14642
- 募集
- Ep0162 50034
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28204
- 募集
- Ep0162 50514
-
Charlotte、North Carolina、アメリカ、28207
- 引きこもった
- Ep0162 50487
-
Durham、North Carolina、アメリカ、27705
- 募集
- Ep0162 50715
-
-
Ohio
-
Akron、Ohio、アメリカ、44308
- 引きこもった
- Ep0162 50371
-
Cleveland、Ohio、アメリカ、44195
- 引きこもった
- Ep0162 50528
-
-
Oregon
-
Portland、Oregon、アメリカ、97239-3098
- 引きこもった
- Ep0162 50510
-
Portland、Oregon、アメリカ、97227
- 完了
- Ep0162 50724
-
Portland、Oregon、アメリカ、97239
- 募集
- Ep0162 50701
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- 募集
- Ep0162 50096
-
Philadelphia、Pennsylvania、アメリカ、19107
- 募集
- Ep0162 50364
-
Philadelphia、Pennsylvania、アメリカ、19140
- 募集
- Ep0162 50089
-
Pittsburgh、Pennsylvania、アメリカ、15212
- 募集
- Ep0162 50511
-
Pittsburgh、Pennsylvania、アメリカ、15213
- 募集
- Ep0162 50491
-
-
Tennessee
-
Chattanooga、Tennessee、アメリカ、37403
- 募集
- Ep0162 50700
-
Memphis、Tennessee、アメリカ、38103-2800
- 募集
- Ep0162 50513
-
Nashville、Tennessee、アメリカ、37232
- 募集
- Ep0162 50103
-
-
Texas
-
Austin、Texas、アメリカ、78749
- 募集
- Ep0162 50731
-
Houston、Texas、アメリカ、77459
- 募集
- Ep0162 50525
-
Houston、Texas、アメリカ、77030
- 募集
- Ep0162 50714
-
Round Rock、Texas、アメリカ、78681
- 引きこもった
- Ep0162 50496
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84132
- 募集
- Ep0162 50473
-
-
Virginia
-
Winchester、Virginia、アメリカ、22601
- 募集
- Ep0162 50726
-
-
-
-
-
Birmingham、イギリス
- 募集
- Ep0162 40686
-
Cardiff、イギリス
- 引きこもった
- Ep0162 40300
-
Glasgow、イギリス
- 募集
- Ep0162 40735
-
London、イギリス
- 募集
- Ep0162 40833
-
Oxford、イギリス
- 募集
- Ep0162 40163
-
Salford、イギリス
- 募集
- Ep0162 40108
-
-
-
-
-
Catanzaro、イタリア
- 引きこもった
- Ep0162 40690
-
Genova、イタリア
- 募集
- Ep0162 40674
-
Milan、イタリア
- 募集
- Ep0162 40144
-
Pavia、イタリア
- 募集
- Ep0162 40477
-
Roma、イタリア
- 募集
- Ep0162 40257
-
Roma、イタリア
- 募集
- Ep0162 40675
-
-
-
-
-
Fitzroy、オーストラリア
- 募集
- Ep0162 30016
-
Herston、オーストラリア
- 募集
- Ep0162 30030
-
Melbourne、オーストラリア
- 引きこもった
- Ep0162 30027
-
South Brisbane、オーストラリア
- 積極的、募集していない
- Ep0162 30031
-
-
-
-
-
Barcelona、スペイン
- 募集
- Ep0162 40160
-
L'Hospitalet de Llobregat、スペイン
- 募集
- Ep0162 40157
-
Madrid、スペイン
- 募集
- Ep0162 40540
-
Pamplona、スペイン
- 募集
- Ep0162 40352
-
Seville、スペイン
- 募集
- Ep0162 40668
-
Terrassa、スペイン
- 募集
- Ep0162 40453
-
Valencia、スペイン
- 募集
- Ep0162 40230
-
Valladolid、スペイン
- 完了
- Ep0162 40667
-
-
-
-
-
Brno、チェコ
- 募集
- Ep0162 40670
-
Ostrava - Poruba、チェコ
- 募集
- Ep0162 40672
-
Prague、チェコ
- 募集
- Ep0162 40671
-
Prague、チェコ
- 募集
- Ep0162 40714
-
Prague、チェコ
- 完了
- Ep0162 40063
-
-
-
-
-
Aachen、ドイツ
- 引きこもった
- Ep0162 40577
-
Berlin、ドイツ
- 募集
- Ep0162 40683
-
Bielefeld、ドイツ
- 募集
- Ep0162 40685
-
Erlangen、ドイツ
- 募集
- Ep0162 40023
-
Frankfurt am Main、ドイツ
- 募集
- Ep0162 40645
-
Kehl-kork、ドイツ
- 完了
- Ep0162 40689
-
Marburg、ドイツ
- 募集
- Ep0162 40529
-
München、ドイツ
- 引きこもった
- Ep0162 40724
-
-
-
-
-
Balassagyarmat、ハンガリー
- 募集
- Ep0162 40666
-
Budapest、ハンガリー
- 募集
- Ep0162 40673
-
Budapest、ハンガリー
- 募集
- Ep0162 40704
-
Debrecen、ハンガリー
- 募集
- Ep0162 40653
-
-
-
-
-
Bron、フランス
- 募集
- Ep0162 40681
-
Bron、フランス
- 引きこもった
- Ep0162 40688
-
Dijon、フランス
- 引きこもった
- Ep0162 40680
-
Marseille、フランス
- 引きこもった
- Ep0162 40130
-
Paris、フランス
- 募集
- Ep0162 40682
-
Paris、フランス
- 引きこもった
- Ep0162 40019
-
Rennes、フランス
- 募集
- Ep0162 40201
-
Strasbourg、フランス
- 募集
- Ep0162 40199
-
-
-
-
-
Blagoevgrad、ブルガリア
- 募集
- Ep0162 40650
-
Pazardzhik、ブルガリア
- 募集
- Ep0162 40708
-
Pleven、ブルガリア
- 完了
- Ep0162 40665
-
Pleven、ブルガリア
- 完了
- Ep0162 40709
-
Sofia、ブルガリア
- 完了
- Ep0162 40651
-
-
-
-
-
Bydgoszcz、ポーランド
- 募集
- Ep0162 40707
-
Gdansk、ポーランド
- 募集
- Ep0162 40677
-
Krakow、ポーランド
- 引きこもった
- Ep0162 40219
-
Krakow、ポーランド
- 募集
- Ep0162 40842
-
Krakow、ポーランド
- 完了
- Ep0162 40502
-
Lublin、ポーランド
- 完了
- Ep0162 40676
-
Nowa Sól、ポーランド
- 募集
- Ep0162 40091
-
Poznan、ポーランド
- 引きこもった
- Ep0162 40153
-
Świdnik、ポーランド
- 完了
- Ep0162 40678
-
-
-
-
-
Beijing、中国
- 募集
- Ep0162 20246
-
Beijing、中国
- 募集
- Ep0162 20299
-
Beijing、中国
- 引きこもった
- Ep0162 20128
-
Beijing、中国
- 完了
- Ep0162 20268
-
Changchun、中国
- 募集
- Ep0162 20261
-
Chengdu、中国
- 募集
- Ep0162 20133
-
Chengdu、中国
- 募集
- Ep0162 20137
-
Chongqing、中国
- 引きこもった
- Ep0162 20250
-
Chongqing、中国
- 募集
- Ep0162 20334
-
Fuzhou、中国
- 募集
- Ep0162 20179
-
Guangzhou、中国
- 募集
- Ep0162 20269
-
Guangzhou、中国
- 募集
- Ep0162 20300
-
Guangzhou、中国
- 募集
- Ep0162 20124
-
Guangzhou、中国
- 完了
- Ep0162 20260
-
Guangzhou、中国
- 完了
- Ep0162 20264
-
Hangzhou、中国
- 募集
- Ep0162 20022
-
Kunming、中国
- 募集
- Ep0162 20320
-
Lanzhou、中国
- 募集
- Ep0162 20258
-
Nanchang、中国
- 引きこもった
- Ep0162 20253
-
Nanjing、中国
- 募集
- Ep0162 20267
-
Nanning、中国
- 募集
- Ep0162 20331
-
Qingdao、中国
- 募集
- Ep0162 20333
-
Shanghai、中国
- 引きこもった
- Ep0162 20123
-
Shanghai、中国
- 募集
- Ep0162 20292
-
Shenzhen、中国
- 引きこもった
- Ep0162 20332
-
Shijiazhuang、中国
- 募集
- Ep0162 20289
-
Suzhou、中国
- 募集
- Ep0162 20119
-
Tianjin、中国
- 募集
- Ep0162 20257
-
Wenzhou、中国
- 募集
- Ep0162 20025
-
Wuhan、中国
- 引きこもった
- Ep0162 20252
-
Yinchuan、中国
- 引きこもった
- Ep0162 20255
-
Zhanjiang、中国
- 募集
- Ep0162 20262
-
Zhengzhou、中国
- 募集
- Ep0162 20251
-
-
-
-
-
Fukuoka、日本
- 募集
- Ep0162 20248
-
Hachioji-shi、日本
- 募集
- Ep0162 20070
-
Hamamatsu、日本
- 引きこもった
- Ep0162 20237
-
Hiroshima、日本
- 募集
- Ep0162 20249
-
Hōfu、日本
- 募集
- Ep0162 20236
-
Itami、日本
- 募集
- Ep0162 20239
-
Kodaira、日本
- 募集
- Ep0162 20143
-
Koshi-shi、日本
- 募集
- Ep0162 20315
-
Kyoto、日本
- 募集
- Ep0162 20147
-
Nagakute、日本
- 完了
- Ep0162 20243
-
Nagoya、日本
- 募集
- Ep0162 20235
-
Niigata、日本
- 募集
- Ep0162 20238
-
Osaka、日本
- 募集
- Ep0162 20302
-
Sapporo、日本
- 募集
- Ep0162 20316
-
Shimotsuga-gun、日本
- 募集
- Ep0162 20337
-
Shinjuku-ku、日本
- 募集
- Ep0162 20297
-
Shizuoka、日本
- 募集
- Ep0162 20240
-
Suita、日本
- 募集
- Ep0162 20242
-
Tōon、日本
- 募集
- Ep0162 20266
-
Yamagata、日本
- 募集
- Ep0162 20244
-
Ōmura、日本
- 募集
- Ep0162 20241
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Participant must be ≥12 years of age at the Baseline/Randomization Visit
-
Participant must have a study caregiver ≥18 years of age at the Screening Visit; the study caregiver(s) must be a relative, partner, friend, or legally authorized representative (LAR) of the participant, or a person who provides daily care to the participant and has a significant personal relationship with the participant; the study caregiver(s) must be able to recognize and observe the participant's seizures
-
Participants with an established diagnosis of focal or generalized epilepsy or combined focal and generalized epilepsy with a documented history of stereotypical episodes of prolonged seizures that includes at least 1 of the following:
- Generalized seizure episodes starting with a flurry of absence seizures or myoclonic seizures with a minimum total duration of 5 minutes
- Episodes of a focal seizure with a minimum duration of 3 minutes
- Episodes of a focal seizure or a flurry of myoclonic seizures for at least 90 seconds followed by a generalized/bilateral tonic-clonic seizure with a minimum total duration of 3 minutes
-
Prior to the Screening Visit, participant has experienced ≥4 stereotypical episodes of prolonged seizures in the past 6 months, and the last 2 stereotypical episodes of prolonged seizures must have occurred within the 3 months prior to the Screening Visit
-
Participant has had a documented brain computerized tomography or magnetic resonance imaging review, performed after diagnosis of epilepsy and within the 5 years prior to the Screening Visit, that confirms the absence of a progressive neurological disorder
-
Participant is receiving a regimen of antiseizure medications (ASMs) that has been stable (ie, no addition or removal of ASM[s]; dose adjustments are permitted to ASM[s]; dose adjustments are not permitted for benzodiazepines) for 30 days prior to the Screening Visit
-
Male and female participants:
- A male participant must agree to use contraception during the Outpatient Treatment Period and for at least 7 days after IMP administration and refrain from donating sperm during this period
- A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:
i) Not a woman of childbearing potential (WOCBP) OR ii) A WOCBP who agrees to follow the contraceptive guidance during the Outpatient Treatment Period and for at least 30 days after IMP administration
-
Participant is capable of giving signed informed consent (or giving assent, where required), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF), the protocol, and the individualized participant management plan (iPMP). The ICF or a specific assent form, where required, will be signed and dated by minors
-
The participant's study caregiver(s) must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF, the protocol, and the iPMP
Exclusion Criteria:
- Participant has a current history of alcohol or drug use disorder, as defined in the Diagnostic and Statistical Manual of Mental Disorders 5, within the previous 1 year
- Participant has a known hypersensitivity to any components of the IMP or comparable drugs (and/or an investigational device) as stated in this protocol or to albuterol (or similar bronchospasm rescue medication if needed to meet country-specific requirements)
- Participant has a diagnosis of atrial fibrillation or mitral stenosis
- Participant has a history of convulsive (generalized tonic-clonic) status epilepticus in the 8 weeks prior to the Screening Visit
- Participant has a history or presence of known nonepileptic seizures which cannot be distinguished from qualifying epileptic seizures
- Participant has a clinically significant known airway hypersensitivity (eg, bronchospasm to known allergens, such as pollen, animals, or food) and/or acute respiratory signs/symptoms (eg, shortness of breath, wheezing on lung auscultation)
- Participant has a clinically significant chronic pulmonary disorder other than mild asthma (eg, chronic obstructive pulmonary disease, restrictive lung diseases [including idiopathic pulmonary fibrosis]) and/or recent history or presence of hemoptysis or pneumothorax
- Participant has had a positive antigen test for acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and experienced moderate to severe signs/symptoms of respiratory distress necessitating hospitalization or outpatient treatment such as ambulatory oxygen, extensive treatment with inhaler medications, and/or oral medications for a duration of 4 weeks or more, unless full resolution occurred at least 6 months prior to Screening
- Participant has experienced a upper respiratory tract infection within 4 weeks or bronchitis/pneumonia within 3 months before the Screening Visit
- Participant has a history or presence of acute narrow-angle glaucoma
- Participant has a condition for which oral alprazolam is contraindicated (eg, myasthenia gravis, severe respiratory insufficiency, and sleep apnea syndrome)
- Participant has a history or presence of long QT syndrome, a family history of sudden death due to long QT syndrome, or unexplained syncope
- Chronic use of benzodiazepines for more than 3 days within a period of 7 days will be allowed for approximately 30 % of study participants
- Participant is taking any drug that is a strong CYP3A4 inhibitor, including azole antifungal agents (ketoconazole and itraconazole) and nefazodone
- Participant is taking any opioids (eg, fentanyl, oxycodone, morphine) or sedative hypnotics on a chronic basis
- Participant is taking nonselective beta blockers on a chronic basis
- Participant is taking pharmacotherapy for an active major psychiatric disorder where major changes in regimen are needed or anticipated during the study
- Participant has been treated with vagal nerve stimulation (VNS) for less than 6 months or VNS settings have changed within 30 days before the Screening Visit
- Participant has a clinically significant laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results, according to the judgment of the Investigator
- Participant has an oxygen saturation <95 % (or less than normal in regions of altitude >2500 meters) for greater than 30 seconds during the Screening Visit. In case of an out-of-range result, 1 repeat will be allowed. If the readings are out of range again, the study participant will be excluded
- Participant has >2.0x upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >1.0xULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert's syndrome or >2.0xULN total bilirubin for liver impairment)
- Participant has current unstable liver or biliary disease per Investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis
- Participant has a QT interval corrected for heart rate (QTc) >450 msec (males), QTc interval >470 msec (females), or QTc interval >480 msec (participants with bundle branch block), PR interval ≥220 msec, or any other clinically significant electrocardiogram (ECG) abnormality according to the Investigator i) The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF). It is either machine-read or manually over-read
- Participant has a positive urine screen for drugs of abuse at the Screening Visit
- Participant has a blood pressure (BP) or heart rate (HR) outside the following range after 5 minutes rest: systolic BP: 90 mmHg to 150 mmHg; diastolic BP: 4 0mmHg to 95 mmHg; HR: 50 bpm to 100 bpm. In case of an out-of-range result, 1 repeat will be allowed. If the readings are out of range again, the study participant will be excluded
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Staccato alprazolam Arm
Participants randomized to this arm will receive a single dose of Staccato alprazolam by inhalation. |
Route of administration: Inhalation Participants will receive one dose of Staccato alprazolam during the Treatment Period.
他の名前:
|
|
プラセボコンパレーター:Placebo Arm
Participants randomized to this arm will receive a single dose of placebo by inhalation. |
Route of administration: Inhalation Participants will receive one dose of placebo during the Treatment Period. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Treatment success for the treated seizure within 90 seconds after investigational medicinal product (IMP) administration
時間枠:From start of IMP treatment through 6 hours
|
Treatment success for the treated seizure is defined as termination of the seizure within 90 seconds after IMP administration. |
From start of IMP treatment through 6 hours
|
|
Treatment success for the treated seizure with no recurrence up to 2 hours
時間枠:From start of IMP treatment through 2 hours
|
Treatment success for the treated seizure is defined as termination of the treated seizure within 90 seconds after IMP administration and no recurrence of seizure(s) from IMP administration to 2 hours after IMP administration and no initiation of seizure rescue treatment from 90 seconds to 2 hours after IMP administration. |
From start of IMP treatment through 2 hours
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Treatment success for treated seizure with no recurrence after 4 hours
時間枠:From start of IMP treatment through 4 hours
|
Treatment success defined as termination of the treated seizure within 90 seconds after IMP administration, with no recurrence of seizure(s) up to 4 hours after IMP administration and no initiation of seizure rescue treatment from 90 seconds to 4 hours after IMP administration. |
From start of IMP treatment through 4 hours
|
|
Treatment success for treated seizure with no recurrence after 6 hours
時間枠:From start of IMP treatment through 6 hours
|
Treatment success defined as termination of the treated seizure within 90 seconds after IMP administration, with no recurrence of seizure(s) up to 6 hours after IMP administration and no initiation of seizure rescue treatment from 90 seconds to 6 hours after IMP administration. |
From start of IMP treatment through 6 hours
|
|
Time from IMP administration to cessation of the treated seizure
時間枠:From start of IMP treatment through 6 hours
|
The time will be assessed from IMP administration to cessation of the treated seizure (taking administration of seizure rescue treatment as censoring point). |
From start of IMP treatment through 6 hours
|
|
Frequency of respiratory treatment emergent adverse events (TEAEs)
時間枠:From start of IMP treatment up to the Safety Follow-up Visit (Week 19)
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. |
From start of IMP treatment up to the Safety Follow-up Visit (Week 19)
|
|
Number of subsequent seizure(s) up to 2 hours after IMP administration
時間枠:From start of IMP treatment through 2 hours
|
The number of subsequent seizure(s) will be assessed up to 2 hours after IMP administration. |
From start of IMP treatment through 2 hours
|
|
Time to first subsequent seizure up to 2 hours after IMP administration
時間枠:From start of IMP treatment through 2 hours
|
The time to first subsequent seizure will be assessed up to 2 hours after IMP administration and is defined as time from end of IMP treated seizure to start of first subsequent seizure. |
From start of IMP treatment through 2 hours
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:UCB Cares、001 844 599 2273 (UCB)
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- EP0162
- 2021-002686-18 (EudraCT番号)
- U1111-1303-2588 (その他の識別子:Universal Trial Number (UTN))
- 2024-510950-29 (レジストリ識別子:EU CT Number)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of reidentifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
IPD 共有時間枠
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
IPD 共有アクセス基準
Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。